Physician profile
Fanping Wang
NPI 1710948112
$15,514.40
in general payments reported to CMS, 2019-2025
39 companies · $1,618 in 2025
The $1,618 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,455 · 2020: $1,863 · 2021: $3,014 · 2022: $2,381 · 2023: $1,962 · 2024: $2,222 · 2025: $1,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,801.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,083.60 | 2019-2025 | Repatha, Repatha, Tepezza |
| Astrazeneca Pharmaceuticals Lp | $1,653.01 | 2019-2025 | Farxiga, Wainua, Andexxa |
| Novartis Pharmaceuticals Corporation | $1,596.95 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,285.48 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $1,099.22 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $968.89 | 2019-2023 | |
| Pfizer INC. | $884.75 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $855.78 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $818.22 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $593.20 | 2019-2024 | Amplatzer Amulet, Aveir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.32 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $364.72 | 2019-2023 | |
| Boston Scientific Corporation | $336.48 | 2019-2025 | Watchman Access System, Bodyguardian |
| Alnylam Pharmaceuticals INC. | $280.83 | 2021-2025 | Onpattro, Amvuttra |
| Novo Nordisk INC | $252.32 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fanping Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.